Hypoxia is not only a prominent contributor to the heterogeneity of solid tumors but also a
crucial stressor in the microenvironment to drive adaptations for tumors to evade …

Gut bacteria modulate the response to immune checkpoint blockade (ICB) treatment in cancer,
but the effect of diet and supplements on this interaction is not well studied. We assessed …

T cell–mediated immunotherapies are promising cancer treatments. However, most patients
still fail to respond to these therapies. The molecular determinants of immune resistance are …

Antibody blockade of the inhibitory CTLA-4 pathway has led to clinical benefit in a subset of
patients with metastatic melanoma. Anti-CTLA-4 enhances T cell responses, including …

The progression from neoplastic initiation to malignancy happens in part because of the
failure of immune surveillance. Cancer cells successfully escape immune recognition and …

Several major challenges currently impede the clinical efficacy of neoantigen-directed
immunotherapy, such as the relative infrequency of immunogenic neoantigens, suboptimal …

Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly
distinct, clinically relevant subtypes: two associated with poor-prognosis monosomy 3 (M3…

Immune checkpoint blockade produces clinical benefit in many patients. However, better
biomarkers of response are still needed, and mechanisms of resistance remain incompletely …

Sarcomas are a broad family of mesenchymal malignancies exhibiting remarkable histologic
diversity. We describe the multi-platform molecular landscape of 206 adult soft tissue …

Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, with poor
prognosis and limited treatment options. Here, we describe the integrated analysis of somatic …